DEF 14A: Merit Medical Systems Seeks Shareholder Approval for Incentive Plan Expansion, Board Nominations Highlighted in Proxy Statement

Merit Medical Systems is soliciting proxies for its upcoming annual meeting, featuring proposals for director elections, executive compensation, and an increase in shares authorized under its long-term incentive plan.

Summary

• Merit Medical Systems has released its proxy statement for the 2024 Annual Meeting of Shareholders, scheduled for May 15, 2024.
• The meeting will be held virtually.
• Shareholders will vote on the election of three directors, an advisory vote on executive compensation (Say-on-Pay), an amendment to increase the number of shares authorized for issuance under the 2018 Long-Term Incentive Plan by 3,000,000 shares, and the ratification of Deloitte & Touche LLP as the company's independent registered public accounting firm.
• The Board of Directors recommends voting FOR all proposals.
• The proxy statement highlights the company's 2023 performance, including revenue of $1.257 billion and operating cash flow of $145 million.
• The company completed the final year of its Foundations for Growth Program, delivering or exceeding all financial targets outlined for the three-year period ended December 31, 2023.
• The proxy statement also details corporate governance practices, director compensation, and executive compensation.
• The Board is seeking approval to increase the number of shares authorized under the 2018 Long-Term Incentive Plan by 3,000,000 shares, believing it's crucial for attracting and retaining talented individuals.
• The company's executive compensation program is designed to align the interests of executives and shareholders, with a significant portion of executive equity compensation tied to the achievement of operating cash flow metrics and stock performance relative to the Russell 2000 market index.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook, highlighting strong financial performance and strategic initiatives. However, it also acknowledges certain risks and challenges, resulting in a moderately positive sentiment score.

Positives

• The company achieved strong operating and financial results, including record revenues and improved non-GAAP operating margin.
• The company completed the Foundations for Growth program, exceeding goals for revenue growth, operating margin expansion, and free cash flow generation.
• The company issued $747.5 million aggregate principal amount of 3.00% Convertible Senior Notes due 2029.
• The company completed acquisitions to strengthen its positions in the dialysis and biopsy markets.
• The company achieved a cumulative total return on its Common Stock from December 31, 2018 to December 31, 2023 of approximately 36%.
• The company received FDA Breakthrough Device Designation for the SCOUT MD TM Surgical Guidance System.
• The company continued initiatives to improve employee training, health and safety and reduce its environmental footprint.

Risks

• Most of the company's products are disposable medical devices and are generally discarded after a single use, leading to potential environmental concerns.
• The company faces climate risks and opportunities that impact its long-term resiliency as a global medical device leader.
• The company recognizes that corruption and unethical conduct of any kind undermines its integrity and reputation and is contrary to its values and long-term success.

Future Outlook

The company has developed the Continued Growth Initiatives Program, reflecting its commitment to position the company for long-term, sustainable growth and enhanced profitability, which was publicly announced on February 28, 2024.

Management Comments

• Fred P. Lampropoulos, Chair of the Board, President, and Chief Executive Officer, stated that the company completed an impressive year of operating and financial performance in 2023.
• Mr. Lampropoulos highlighted the completion of the Foundations for Growth Program, delivering or exceeding each of the financial targets outlined for the three-year period ended December 31, 2023.

Industry Context

The document provides insight into Merit Medical's performance relative to its peers in the medical device industry, particularly in the context of executive compensation and corporate governance practices.

Comparison to Industry Standards

• The Compensation Committee reviews industry and peer compensation data for medical device companies to confirm that executive compensation is within an appropriate competitive range.
• The peer group used for 2023 executive compensation decisions consisted of companies such as CONMED Corporation, Globus Medical, Inc., ICU Medical, Inc., Inari Medical, Inc., Insulet Corporation, Integer Holdings Corporation, Integra LifeSciences Holdings Corporation, LivaNova Plc, Masimo Corporation, Nevro Corp, NuVasive, Inc., Penumbra, Inc., QuidelOrtho Corporation, Shockwave Medical, Inc., and Teleflex Incorporated.
• The Compensation Committee has set the base salary and incentive cash bonus of the CEO at levels which are higher than the aggregate amount of base salary and incentive bonus paid to the principal executive officers of a number of our peers.

Related Party Transactions

• Joseph C. Wright, Chief Commercial Officer of the Company, is the brother-in-law of Fred P. Lampropoulos, Chair of the Board, CEO and President of the Company.
• In 2023, we provided to Mr. Wright total cash and equity compensation of $2,814,511.
• The Board, acting through the Audit Committee, believes that the Related Person Transaction between the Company and Mr. Wright is reasonable and fair to the Company.

Stakeholder Impact

• The company's performance and strategic initiatives impact shareholders, employees, customers, and the communities in which it operates.
• The company is committed to improving lives around the globe through financial contributions, employee time and dedication, and collaboration with global and local non-profit organizations.

Next Steps

• Shareholders are encouraged to vote on the proposals outlined in the proxy statement.
• The company will hold its Annual Meeting of Shareholders on May 15, 2024.
• The company intends to release its 2023 Sustainability Report in May 2024.
• The Board will continue to seek opportunities to consult with major shareholders in appropriate situations.

Key Dates

Keywords

executive compensation, proxy statement, corporate governance, director election, incentive plan, annual meeting, financial performance, Merit Medical Systems